Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024. In the quarter to June 2026, revenue grew 294.3%, EPS fell 2.27% and free cash flow fell 105.4%, each against the same quarter a year earlier.
Follow DNTH
Dianthus Therapeutics, Inc. (DNTH) EV/Sales
As of 16 October 2026, Dianthus Therapeutics, Inc. (DNTH) trades at a EV/Sales of 1,656×. Over the past ten years it has ranged from −40.6× (January 2024) to 2,947× (August 2026); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 583× | 706.09% |
| FY2024 | 72.3× | — |
| FY2023 | −40.6× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2,403× | 9.95% |
| Mar 2026 | 2,185× | 274.80% |
| Dec 2025 | 583× | 65.47% |
| Sep 2025 | 352× | 317.19% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DFTX Definium Therapeutics, Inc. compare | n/m |
| TLX Telix Pharmaceuticals Limited compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 2.2× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| TNGX Tango Therapeutics, Inc. compare | 36.7× |
| ABCL AbCellera Biologics Inc. compare | 46.0× |
| RLAY Relay Therapeutics, Inc. compare | 217× |
| DNTH Dianthus Therapeutics, Inc. | 1,656× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)